TG-1801

· TG Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TG-1801, covering 2024-07-31 to 2024-07-31. Get the full timeline:

Most recent: Clinical Trial Update: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]

See pricing